"It is worth highlighting that MESO has several strategic partnerships that should expedite its IP’s access to worldwide markets. These agreements include collaborations to develop and commercialize its MSC therapies. For instance, JCR Pharmaceuticals (OTCPK:JCRRF) is entitled to generate MSC therapies for hematological malignancies like GvHD and Hypoxic ischemic encephalopathy [HIE]. Grünenthal holds the exclusive license for Rexlemestrocel-L for treating CLBP in Europe, Latin America, and the Caribbean. Finally, Tasly Pharmaceuticals has exclusive rights over Rexlemestrocel-L for HFrEF medicine in China."
GLTLH
Molly
MSB Price at posting:
$1.39 Sentiment: Buy Disclosure: Held
